Literature DB >> 15363998

Pharmacological characterisation of the thermogenic effect of bupropion.

Yong-Ling Liu1, Ian P Connoley, David J Heal, Michael J Stock.   

Abstract

The pharmacological mechanism of bupropion's thermogenic effect has been investigated in female Wistar rats by measuring oxygen consumption at thermoneutrality (29 degrees C). Bupropion (30 mg/kg) rapidly increased oxygen consumption (VO2) with a maximum effect at 30 min, and VO2 remained elevated throughout the 4-h experimental period. The nonselective 5-hydroxytryptamine (5-HT or serotonin) receptor antagonist, metergoline (1 mg/kg), and the alpha1-adrenoceptor antagonist, prazosin (1 mg/kg), had no effect on the VO2 response to bupropion, whereas the alpha2-adrenoceptor antagonist, RS79948 [(8aR, 12aS, 13aS)-5,8,8a,9,10,11,12,12a,13,13a-decahydro-3-methoxy-12-(ethylsulphonyl)-6H-isoquino[2,1-g][1,6]-naphthyridine hydrochloride] (1 mg/kg), potentiated the response. The VO2 response to bupropion during the first 60 min was significantly inhibited by a high dose of the nonselective beta-adrenoceptor antagonist, propranolol (20 mg/kg), but it had no effect at a low dose (1 mg/kg). Pretreatment with the dopamine D2/D1 receptor antagonist, (+)butaclamol (200 microg/kg), caused a partial, but significant, inhibition (P<0.01) of the VO2 response to bupropion during the first 60 min, and this antagonist abolished the effect of bupropion between 90 and 240 min. Pretreatment with a combination of a high dose of propranolol (20 mg/kg) and (+)butaclamol (200 microg/kg) prevented any increase in VO2 induced by bupropion. It is concluded that the beta3-adrenoceptor subtype, as well as dopamine D2/D1 receptors, is responsible for the increase in oxygen consumption induced by bupropion. We have previously demonstrated that bupropion did not significantly reduce food intake in rats. Hence, in this species, its weight-reducing action predominantly results from thermogenesis mediated via activation of beta3-adrenergic and dopamine D2/D1 receptors. Because bupropion has also been reported not to alter food intake in the clinic, thermogenesis may also contribute to its antiobesity effect in man.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15363998     DOI: 10.1016/j.ejphar.2004.07.004

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat.

Authors:  Anne Marie D Axel; Jens D Mikkelsen; Henrik H Hansen
Journal:  Neuropsychopharmacology       Date:  2010-03-03       Impact factor: 7.853

2.  Is serotonin uptake by peripheral tissues sensitive to hypoxia exposure?

Authors:  Molly H B Amador; M Danielle McDonald
Journal:  Fish Physiol Biochem       Date:  2022-05-18       Impact factor: 2.794

3.  In vivo oxymetric analysis of mild hypercapnia upon cerebral oxygen, temperature and blood flow: markers of mood as proposed by concomitant bupropion challenge and electrochemical analysis?

Authors:  Francesco Crespi
Journal:  Exp Brain Res       Date:  2013-03-17       Impact factor: 1.972

4.  Metabolic and Cardiovascular Benefits and Risks of EMD386088-A 5-HT6 Receptor Partial Agonist and Dopamine Transporter Inhibitor.

Authors:  Magdalena Kotańska; Joanna Śniecikowska; Magdalena Jastrzębska-Więsek; Marcin Kołaczkowski; Karolina Pytka
Journal:  Front Neurosci       Date:  2017-02-08       Impact factor: 4.677

5.  FoxO1 in dopaminergic neurons regulates energy homeostasis and targets tyrosine hydroxylase.

Authors:  Khanh V Doan; Ann W Kinyua; Dong Joo Yang; Chang Mann Ko; Sang Hyun Moh; Ko Eun Shong; Hail Kim; Sang-Kyu Park; Dong-Hoon Kim; Inki Kim; Ji-Hye Paik; Ronald A DePinho; Seul Gi Yoon; Il Yong Kim; Je Kyung Seong; Yun-Hee Choi; Ki Woo Kim
Journal:  Nat Commun       Date:  2016-09-29       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.